Search results for "VIE"

showing 10 items of 11648 documents

Cadmium-Associated Molecular Signatures in Cancer Cell Models

2021

Simple Summary The exposure of cancer cells to cadmium compounds may be associated with the acceleration of tumor progression. It is known that cadmium is a transcriptional regulator, and the study of differentially expressed genes has enabled the identification and classification of cadmium-associated molecular signatures as useful biomarkers that are potentially transferable to clinical research. This review recapitulates the studies that report the detection of such signatures in breast, gastric, colon, liver, lung, and nasopharyngeal tumor cell models, as specifically demonstrated by individual gene or whole genome expression profiling. Abstract The exposure of cancer cells to cadmium a…

0301 basic medicineCancer Researchcadmiumnasopharyngeal cancerReviewBiologygene signaturedifferential expressionliver cancer03 medical and health sciences0302 clinical medicinebreast cancerGene silencingSettore BIO/06 - Anatomia Comparata E CitologiaRC254-282Regulation of gene expressiongastric cancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensGene signaturein vitro cell modelsPhenotypein vitro cell modelGene expression profilinglung cancer030104 developmental biologyOncologycolon cancerTumor progression030220 oncology & carcinogenesisCancer cellCancer researchReprogrammingCancers
researchProduct

Cancer Acidity and Hypertonicity Contribute to Dysfunction of Tumor-Associated Dendritic Cells: Potential Impact on Antigen Cross-Presentation Machin…

2020

Macrophages (M) and dendritic cells (DC), major players of the mononuclear phagocyte system (MoPh), are potent antigen presenting cells that steadily sense and respond to signals from the surrounding microenvironment, leading to either immunogenic or tolerogenic outcomes. Next to classical MHC-I/MHC-II antigen-presentation pathways described in the vast majority of cell types, a subset of MoPh (CD8+, XCR1+, CLEC9A+, BDCA3+ conventional DCs in human) is endowed with a high competence to cross-present external (engulfed) antigens on MHC-I molecules to CD8+ T-cells. This exceptional DC function is thought to be a crucial crossroad in cytotoxic antitumor immunity and has been extensively studie…

0301 basic medicineCancer Researchcancer acidityReviewMajor histocompatibility complexlcsh:RC254-28203 medical and health sciences0302 clinical medicineAntigenCytotoxic T celltumor microenvironmentAntigen-presenting cellcross-presentationTumor microenvironmentbiologyChemistryCross-presentationMononuclear phagocyte systemlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensWarburg effectCell biology030104 developmental biologyOncologyhyperosmolarity030220 oncology & carcinogenesisbiology.proteinCancers
researchProduct

Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets

2019

Uveal Melanoma (UM) represents the most common primary intraocular malignant tumor in adults. Although it originates from melanocytes as cutaneous melanoma, it shows significant clinical and biological differences with the latter, including high resistance to immune therapy. Indeed, UM can evade immune surveillance via multiple mechanisms, such as the expression of inhibitory checkpoints (e.g., PD-L1, CD47, CD200) and the production of IDO-1 and soluble FasL, among others. More in-depth understanding of these mechanisms will suggest potential targets for the design of novel and more effective management strategies for UM patients.

0301 basic medicineCancer Researchimmune-escapemedicine.medical_treatmentReviewlcsh:RC254-282Fas ligand03 medical and health sciences0302 clinical medicineImmune privilegemedicinebusiness.industryMelanomaCD47Effective managementImmunotherapyinhibitory checkpointimmune-privilegemedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensImmune surveillanceimmune-escape; immune-privilege; immunotherapy; inhibitory checkpoints; uveal melanomainhibitory checkpoints030104 developmental biologyOncology030220 oncology & carcinogenesisCutaneous melanomaCancer researchimmunotherapyuveal melanomabusiness
researchProduct

Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer

2020

Simple Summary The outcome for patients with rectal cancer has significantly improved over the last thirty years. Previously, local relapses in the pelvis occurred in more than one third of all patients with apparently localized tumors. Total mesorectal excision was the first step to improve local control by reducing local relapses to less than 5%. Preoperative radiation, either short-course or long-course with concurrent administration of chemotherapy, was a second important step for reducing local relapses to a minimum, even in locally advanced tumors where a clean surgical resection was not possible or would not be curative. Magnetic resonance imaging is a very useful tool for locoregion…

0301 basic medicineCancer Researchmedicine.medical_specialtyColorectal cancermedicine.medical_treatmentLocally advancedReviewlcsh:RC254-282law.inventionMetastasis03 medical and health sciencesMesorectal fascia0302 clinical medicineRandomized controlled triallawmedicinewatch and wait strategyChemotherapyPreoperative chemoradiotherapyPostoperative chemotherapybusiness.industrymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensHigh-risk locally advanced rectal cancer; Total neoadjuvant treatment; Watch and wait strategyhigh-risk locally advanced rectal cancer030104 developmental biologyOncology030220 oncology & carcinogenesisRadiologybusinesstotal neoadjuvant treatmentCancers
researchProduct

Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies

2021

Simple Summary Childhood cancers are mostly of unknown etiology and represent devastating diagnoses. The clinical benefits of steadily increasing tumor control and survival rates are countered by severe and fatal health consequences from genotoxic therapies in long-term survivors of pediatric cancers. Among them, iatrogenic second primary malignancies represent the heaviest burden for the patient. Therefore, particularly in pediatric tumor patients, the reduction of genotoxic treatments and the use of targeted or immune-based oncologic strategies are of high clinical interest. The knowledge of therapy-associated as well as intrinsic risk factors for late sequelae of antineoplastic treatment…

0301 basic medicineCancer Researchmedicine.medical_specialtyetiologymedicine.medical_treatmentPopulationReviewchemotherapyTargeted therapy03 medical and health sciences0302 clinical medicineEpidemiologymedicinechildhood cancerlate-effectseducationIntensive care medicineradiotherapyRC254-282education.field_of_studyChemotherapybusiness.industryCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasetargeted therapyPediatric cancerRadiation therapy030104 developmental biologyOncology030220 oncology & carcinogenesisEtiologyepidemiologyimmunotherapybusinesssecond primary malignancyCancers
researchProduct

Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment

2021

Simple Summary It is now accepted that CD4 T lymphocytes play an essential role in the anti-tumor response. CD4 T lymphocytes can activate and regulate several aspects of innate and adaptive immunity and participate in the rejection of tumors. Understanding the impact of the tumor, through cytokines present in the microenvironment, but also the effect of anti-cancer therapies are critical aspects of immunotherapy research aiming at improving the anti-tumor response dependent on CD4 T lymphocytes. Abstract The advancement of knowledge on tumor biology over the past decades has demonstrated a close link between tumor cells and cells of the immune system. In this context, cytokines have a majo…

0301 basic medicineCancer Researchmedicine.medical_treatmentContext (language use)ReviewBiologylcsh:RC254-28203 medical and health sciences0302 clinical medicineImmune systemmedicinecancerTumor microenvironmentImmunotherapyAcquired immune systemlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPhenotypeCD4cytokines030104 developmental biologyCytokineOncology030220 oncology & carcinogenesisCancer researchimmunotherapyHomeostasisCancers
researchProduct

Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma

2018

The advent of immune checkpoint (ICP) blockade has introduced an unprecedented paradigm shift in the treatment of cancer. Though very promising, there is still a substantial proportion of patients who do not respond or develop resistance to ICP blockade. In vitro and in vivo models are eagerly needed to identify mechanisms to maximize the immune potency of ICP blockade and overcome primary and acquired resistance to ICP blockade. Vγ9Vδ2 T cells isolated from the bone marrow (BM) from multiple myeloma (MM) are excellent tools to investigate the mechanisms of resistance to PD-1 blockade and to decipher the network of mutual interactions between PD-1 and the immune suppressive tumor microenvir…

0301 basic medicineCancer Researchmedicine.medical_treatmentMini Reviewlcsh:RC254-28203 medical and health sciences0302 clinical medicineImmune systemIn vivoMedicinetumor vaccinationVg9Vd2 T cells immune checkpoint blockade immunotherapy tumor vaccination multiple myelomaMultiple myelomaTumor microenvironmentVg9Vd2 T cellsbusiness.industryImmunotherapyimmune checkpoint blockadelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseVγ9Vδ2 T cellsImmune checkpointBlockademultiple myeloma030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchBone marrowimmunotherapybusinessFrontiers in Oncology
researchProduct

Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities

2021

Simple Summary The growing interest in immunotherapy for the treatment of multiple myeloma demands a deep knowledge of the complex interactions between malignant and immune cells within the bone marrow. Indeed, understanding the cellular and molecular mechanisms underlying this network should represent the basis for the design of novel patient-oriented biological therapeutic approaches. Here, we describe the role of the main immune components of the myeloma niche along disease evolution and their implication in impairing/improving the response to anti-cancer treatments. Additionally, we provided an overview of the potential weakness of this pro-tumor interplay, evidencing novel therapeutic …

0301 basic medicineCancer Researchmedicine.medical_treatmentReview03 medical and health sciences0302 clinical medicineMedicinetumor immunologyElotuzumabMultiple myelomaRC254-282IsatuximabMonoclonal antibodiebusiness.industryDaratumumabNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunotherapymedicine.diseasePomalidomideanti-cancer immune responseThalidomidemultiple myeloma030104 developmental biologyOncology030220 oncology & carcinogenesisImmunologyimmunotherapymonoclonal antibodiesbusinessMonoclonal gammopathy of undetermined significancemedicine.drugCancers
researchProduct

Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy

2020

Simple Summary The aim of this review is to detailed immunological effects of chemotherapies focusing on 2 main effects: immunogenic cell death and depletion of suppressive cells. It provides a strong rational for combination of chemotherapy and immunotherapy. Abstract Chemotherapy is initially used to kill proliferative cells. In the current area of emerging immunotherapy, chemotherapies have shown their ability to modulate the tumor micro environment and immune response. We focus here on two main effects: first, immunogenic cell death, defined as a form of regulated cell death (RCD) that is sufficient to activate an adaptive immune response in immunocompetent hosts; and second, the deplet…

0301 basic medicineCancer Researchmedicine.medical_treatmentReviewchemotherapylcsh:RC254-28203 medical and health sciences0302 clinical medicineImmune systemImmunityChemoimmunotherapyimmunogenic cell deathmedicinecancerChemotherapyimmunosuppressionbusiness.industryImmunosuppressionImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensAcquired immune system030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchImmunogenic cell deathimmunotherapybusinessCancers
researchProduct

The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment

2021

Simple Summary Immunotherapy improved the therapeutic landscape for patients with advanced cancer diseases. However, many patients do not benefit from immunotherapy. The bidirectional crosstalk between myeloid-derived suppressor cells (MDSC) and regulatory T cells (Treg) contributes to immune evasion, limiting the success of immunotherapy by checkpoint inhibitors. This review aims to outline the current knowledge of the role and the immunosuppressive properties of MDSC and Treg within the tumor microenvironment (TME). Furthermore, we will discuss the importance of the functional crosstalk between MDSC and Treg for immunosuppression, issuing particularly the role of cell adhesion molecules. …

0301 basic medicineCancer Researchmedicine.medical_treatmentT cellCellReviewBiologylcsh:RC254-282regulatory T cellscrosstalk03 medical and health sciencestumor immune evasion0302 clinical medicinecell–cell contactmedicinetumor microenvironmentReceptorCD18Tumor microenvironmentCell adhesion moleculeImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmyeloid-derived suppressor cells<b>Keywords: </b>myeloid-derived suppressor cellsCrosstalk (biology)030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisβ2 integrinsMyeloid-derived Suppressor CellCancer researchimmunotherapyCD11Cancers
researchProduct